Trial of IFN or STI571 before proceeding to allografting for CML?
Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders. Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantifi...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
31 August 2000
|
| In: |
Leukemia
Year: 2000, Volume: 14, Issue: 9, Pages: 1560-1562 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2401874 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.leu.2401874 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/2401874 
|
| Author Notes: | R. Hehlmann |
| Summary: | Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders. Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantification of survival after BMT and IFN treatment suggests that a trial of IFN (and possibly STI 571) before proceeding to allografting is a viable, and in low risk patients a probably preferable option. |
|---|---|
| Item Description: | Gesehen am 19.05.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2401874 |